Our LPT-CBD technology offers a new approach to managing chronic pain in companion animals. This innovative solution provides long-lasting, effective relief, improving the quality of life for pets.

Addressing a Growing Market

The veterinary pain management market, currently valued at $1.65 billion, is projected to exceed $2.20 billion by 2029. Companion animals represent the largest segment, comprising 85% of this market. Our innovative LPT-CBD technology is well-positioned to address the needs of this growing market.

Efficacy and Safety in Preclinical Studies

Our LPT-CBD technology has demonstrated significant efficacy and safety in preclinical studies focused on chronic pain conditions in companion animals:

• Osteoarthritis and cervical pain in a dog: As part of compassionate care, a single subcutaneous injection of LPT-CBD improved pain score and activity for up to 3 weeks 
• Osteoarthritis-Related Pain in dogs: A single subcutaneous injection of LPT-CBD provided long-term analgesic effects, lasting several weeks
• Pharmacokinetics in dogs: A single LPT-CBD injection maintained CBD plasma concentrations for up to 6 weeks
• Basic Safety in dogs: Safety monitoring, including vital signs, hematology, and serum biochemistry, showed excellent tolerance of LPT-CBD

Regulatory Progress

 We submitted an Investigational New Animal Drug (INAD) application with the FDA’s Center for Veterinary Medicine (CVM), supported by a scientific overview on LPT-CBD  as part of our regulatory pathway [link to Pipeline].

Commitment to Animal Health

 At Innocan, we are dedicated to improving the lives of companion animals through scientific innovation. Our LPT-CBD technology addresses real clinical needs, providing significant pain relief for pets with chronic pain.

 Discover how Innocan is making strides in veterinary pain management with our LPT-CBD technology.